AZD3514

**Cat. No.:** HY-16079  
**CAS No.:** 1240299-33-5  
**Molecular Formula:** C₂₅H₃₂F₃N₇O₂  
**Molecular Weight:** 519.56  
**Target:** Androgen Receptor  
**Pathway:** Others  
**Storage:**  
- Powder: -20°C for 3 years, 4°C for 2 years, In solvent: -80°C for 6 months, -20°C for 1 month

**SOLVENT & SOLUBILITY**

**In Vitro**

DMSO: ≥ 100 mg/mL (192.47 mM)  
*"≥" means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Concentration</th>
<th>Mass</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>1.9247 mL</td>
<td>9.6235 mL</td>
<td>19.2471 mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.3849 mL</td>
<td>1.9247 mL</td>
<td>3.8494 mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.1925 mL</td>
<td>0.9624 mL</td>
<td>1.9247 mL</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO > 40% PEG300 > 5% Tween-80 > 45% saline  
   Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution
2. Add each solvent one by one: 10% DMSO > 90% (20% SBE-β-CD in saline)  
   Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution
3. Add each solvent one by one: 10% DMSO > 90% corn oil  
   Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution

**BIOLOGICAL ACTIVITY**

**Description**  
AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 μM and has ability of reducing AR protein expression. IC50 Value: 2.2 uM (Ki) Target: androgen receptor. AZD3514 binds to the AR ligand binding domain and has selectivity for binding to AR over other nuclear hormone receptors [1]. In vitro: AZD3514 inhibits cell growth in prostate cancer cells expressing wild-type (VCaP) and mutated (T877A) AR (LNCaP), but is inactive in AR-negative prostate cancer cells, indicating a dependency on AR for efficacy [2]. In vivo: We assessed activity initially in the
Hershberger castrated rat assay in which oral dosing of AZD3514 (100mg/kg once-daily for 7 days) significantly inhibited testosterone-induced growth of sexual accessory organs [2]. Clinical trial: Open-label Prostate Cancer Study. Phase 1

CUSTOMER VALIDATION


See more customer validations on www.MedChemExpress.com

REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898  Fax: 609-228-5909  E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA